Hayes, Wesley http://orcid.org/0000-0002-8091-6945
Sas, David J.
Magen, Daniella
Shasha-Lavsky, Hadas
Michael, Mini
Sellier-Leclerc, Anne-Laure
Hogan, Julien
Ngo, Taylor
Sweetser, Marianne T.
Gansner, John M.
McGregor, Tracy L.
Frishberg, Yaacov
Funding for this research was provided by:
Alnylam Pharmaceuticals
Article History
Received: 5 November 2021
Revised: 30 June 2022
Accepted: 1 July 2022
First Online: 1 August 2022
Declarations
:
: The study was approved by the institutional review board or ethics committee at each study site and was conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki.
: Legal guardians provided written informed consent, and patients provided assent per local regulations and institutional standards.
: Not applicable.
: Wesley Hayes: travel and accommodation expenses from Alnylam Pharmaceuticals to attend an international investigators’ meeting. David J. Sas: grants and other from Alnylam Pharmaceuticals; personal fees from Advicenne. Daniella Magen: research funding, consultancy fees, and nonfinancial support from Alnylam Pharmaceuticals. Hadas Shasha-Lavsky: travel and accommodation expenses from Alnylam Pharmaceuticals to attend an international investigators’ meeting. Mini Michael: travel and accommodation expenses from Alnylam Pharmaceuticals to attend an international investigators’ meeting. Anne-Laure Sellier-Leclerc: consultancy fees from Alnylam Pharmaceuticals and Dicerna Pharmaceuticals, and principal investigator for research funded by OxThera. Julien Hogan: consultancy fees from Alnylam Pharmaceuticals. Marianne T. Sweetser, John M. Gansner: employment by and shareholders/stock options of Alnylam Pharmaceuticals. Tracy McGregor, Taylor Ngo: previous employment by and shareholders of Alnylam Pharmaceuticals. Yaacov Frishberg: consultancy fees from Alnylam Pharmaceuticals and membership in the Scientific Review Committee.